Merck Serono Expands Biopharmaceutical R&D Facility
Merck is investing € 65 million in a laboratory building for R&D Discovery Technologies at Merck Serono
Merck KGaA
The new building will unite different functions within R&D Discovery Technologies at Merck Serono, including Molecular Pharmacology, Medicinal Chemistry, Computational Chemistry, Molecular Interactions and Biophysics, Protein Engineering and Antibody Technologies, and Protein and Cell Sciences.
The research building, when complete in fall of 2017, will be located within the new "Pharma Square" on the Merck campus in Darmstadt. Merck is thus uniting a significant part of its R&D activities in a single area, creating ideal conditions for the advancement of its biopharmaceutical pipeline.
With approximately 2,000 scientific and clinical development professionals working across four R&D hubs - Darmstadt, Germany, the largest R&D site; Boston, US; Tokyo, Japan; and Beijing, China - Merck Serono endeavors to make a meaningful difference in the lives of people with serious medical needs. The core areas of R&D focus for Merck Serono are oncology, immuno-oncology, and immunology.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.